Initial viral decay rate may be useful when comparing the relative potency of antiretroviral regimens. Two hundred twenty-seven ART-naïve patients were randomized to receive efavirenz (EFV) (n = 74), lopinavir/ritonavir (LPV/r) (n = 77), or atazanavir/ritonavir (ATV/r) (n = 79) in combination with two NRTIs. The most frequently used NRTI combinations in the EFV and ATV/r groups were the nonthymidine analogues tenofovir and emtricitabine or lamivudine (70% and 68%, respectively) and, in the LPV/r group, lamivudine and the thymidine analogue zidovudine (89%). HIV-1 RNA was monitored during the first 28 days after treatment initiation. Phase 1 and 2 decay rate was estimated in a subset of 157 patients by RNA decrease from days 0 to 7, and days 14 to 28. One-way ANOVA and subsequent Tukey's post hoc tests were used for groupwise comparisons. Mean (95% CI) HIV-1 RNA reductions from days 0 to 28 were 2.59 (2.45–2.73), 2.42 (2.27–2.57), and 2.13 (2.01–2.25) log10 copies/ml for the EFV-, LPV/r-, and ATV/r-based treatment groups, respectively, with a significantly larger decrease in the EFV-based group at all time points compared with ATV/r (p < 0.0001), and with LPV/r at days 7–21 (p < 0.0001–0.03). LPV/r gave a greater RNA decrease compared with ATV/r from day 14 (p = 0.02). Phase 1 decay rate was significantly higher in the EFV group compared with LPV/r (p = 0.003) or ATV/r (p < 0.0001). No difference was found in phase 2 decrease. EFV-based treatment gave a more rapid decline in HIV-1 RNA than did either of the boosted protease inhibitor–based regimens. The observed differences may reflect different inherent regimen potencies.
Get full access to this article
View all access options for this article.
References
1.
HoDD, NeumannAU, PerelsonASet al.Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 1995; 373,6510:123–126.
2.
MaldarelliF, PalmerS, KingMSet al.ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog, 2007; 3,4:e46.
3.
YilmazA. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy. Antivir Ther, 2006; 11:833–837.
4.
PalmerS, MaldarelliF, WiegandAet al.Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A, 2008; 105,10:3879–3884.
5.
PerelsonAS, NeumannAU, MarkowitzMet al.HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science, 1996; 271,5255:1582–1586.
6.
PerelsonAS, EssungerP, CaoYet al.Decay characteristics of HIV-1-infected compartments during combination therapy. Nature, 1997; 387,6629:188–191.
7.
HlavacekWS, StilianakisNI, NotermansDWet al.Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. Proc Natl Acad Sci U S A, 2000; 97,20:10966–10971.
8.
FinziD, BlanksonJ, SilicianoJDet al.Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med, 1999; 5,5:512–517.
9.
SilicianoJD, KajdasJ, FinziDet al.Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 + T cells. Nat Med, 2003; 9,6:727–728.
10.
MarkowitzM, PerelsonAS. HIV-1 viral dynamics studies in the setting of clinical trials: a window of opportunity. J Infect Dis, 2007; 195,8:1087–1088.
11.
HammerSM, EronJJJr, ReissPet al.Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA, 2008; 300,5:555–570.
12.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human ServicesNovember 3, 2008; 1–139http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. 2008November.
13.
ClumeckN, PozniakA, RaffiF. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med, 2008; 9,2:65–71.
14.
JosephsonF, AlbertJ, FlamholcLet al.Antiretroviral treatment of HIV infection: Swedish recommendations 2007. Scand J Infect Dis, 2007; 39,6–7:486–507.
15.
ChesneyMA, IckovicsJR, ChambersDBet al.Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments: Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG)AIDS Care, 2000; 12,3:255–266.
16.
ReynoldsNR, SunJ, NagarajaHNet al.Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: a cross-protocol analysis. J Acquir Immune Defic Syndr, 2007; 46,4:402–409.
17.
KuritzkesDR, RibaudoHJ, SquiresKEet al.Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis, 2007; 195,8:1169–1176.
18.
WuH, LatheyJ, RuanPet al.Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12–22 years) infected through high-risk behavior. J Infect Dis, 2004; 189,4:593–601.
19.
BoydMA, DixitNM, SiangphoeUet al.Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012)J Infect Dis, 2006; 194,9:1319–1322.
20.
BonoraS, NicastriE, CalcagnoAet al.Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol, 2009; 81,3:400–405.
21.
ShenL, PetersonS, SedaghatARet al.Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med, 2008; 14,7:762–766.
22.
SedaghatAR, DinosoJB, ShenLet al.Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A, 2008; 105,12:4832–4837.
23.
ArribasJR, PozniakAL, GallantJEet al.Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr, 2008; 47,1:74–78.
24.
DeJesusE, HerreraG, TeofiloEet al.Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis, 2004; 39,7:1038–1046.
25.
SaxP, TierneyC, CollierAet al.ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naïve subjects with screening HIV RNA 100,000 c/mL. 17th International AIDS Conference: Mexico City, Mexico, 2008.
26.
SmithKY, FineDM, PatelPet al.Similarity in efficacy, safety of abacavir/lamivudine (ABC/3TC) compared to tenofovir/emtricitabine (TDF/FTC) in combination with QD lopinavir/ritonavir (LPV/r) over 96 weeks in the HEAT Study. 17th International AIDS Conference: Mexico City, Mexico, 2008.
27.
ShenL, SilicianoRF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol, 2008; 122,1:22–28.
28.
SankatsingSU, WeverlingGJ, PeetersMet al.TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS, 2003; 17,18:2623–2627.
29.
LouieM, HoganC, Di MascioMet al.Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis, 2003; 187,6:896–900.
30.
PolisMA, SidorovIA, YoderCet al.Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet, 2001; 358,9295:1760–1765.
31.
van LethF, HuisamenCB, BadaroRet al.Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: a 2NN substudy. J Acquir Immune Defic Syndr, 2005; 38,3:296–300.
32.
WuH, MellorsJ, RuanPet al.Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors. J Acquir Immune Defic Syndr, 2003; 33,5:557–563.
33.
RiddlerSA, HaubrichR, DiRienzoAGet al.Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med, 2008; 358,20:2095–2106.
34.
Sierra MaderoJ, VillasisA, MendezPet al.A prospective, randomized, open label trial of efavirenz versus lopinavir/ritonavir based HAART among antiretroviral therapy naïve, HIV-infected individuals presenting for care with CD4 cell counts <200/mm3 in Mexico. 17th International AIDS Conference: Mexico City, Mexico, 2008.
35.
MolinaJM, Andrade-VillanuevaJ, EchevarriaJet al.Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet, 2008; 372,9639:646–655.
100,000 c/mL.